Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. - Test2 - elhamkhani - TriplyDB

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

http://www.wikidata.org/entity/Q33625213

about

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections Anti-HIV-1 nanotherapeutics: promises and challenges for the future Studies of retroviral infection in humanized mice New generation humanized mice for virus research: comparative aspects and future prospects The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice The clinical role and cost-effectiveness of long-acting antiretroviral therapy Humanized mouse models for HIV-1 infection of the CNS.Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice Influence of age, irradiation and humanization on NSG mouse phenotypes.Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice.Migration of CD8+ T Cells into the Central Nervous System Gives Rise to Highly Potent Anti-HIV CD4dimCD8bright T Cells in a Wnt Signaling-Dependent Manner The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.Characterization of neuropathology in the HIV-1 transgenic rat at different ages.HIV-1 cellular and tissue replication patterns in infected humanized mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections HIV-specific CD8⁺ T-cell immunity in humanized bone marrow-liver-thymus mice Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice.An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.Macrophages associated with tumors as potential targets and therapeutic intermediates.Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND)Latest animal models for anti-HIV drug discovery.Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.Brain Invasion by CD4(+) T Cells Infected with a Transmitted/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice.

P2860

Q26766448-D87A8F77-38A5-41B7-997C-9F5CC4B561DC Q26781386-7322DCA7-97F8-41E8-ADA8-909734D211F2 Q26828464-8C460E74-CB22-4906-AF74-5CCEE4293947 Q26849806-C3D3B5E3-F25E-442C-BAAC-AFEEC55CA2A1 Q27014786-F0818D11-1F78-4C6B-AE3B-54B0907F1F60 Q28087336-174952E4-0DD2-4987-8F73-863469451CC4 Q28394163-F6308A30-505A-4242-84BF-9182906EECE8 Q28551873-04222365-4682-42CD-9552-83C2BA05215B Q30603781-33CE2488-1B46-4A5E-8D18-D4AC570D344F Q34059457-8C84AAED-B8AE-43AB-A500-82EE0D183B2E Q34745586-3967E4CD-306B-42C6-B3CB-74007EC9CD13 Q34797004-5C66FD19-0B99-44AF-81A0-731B82AF9854 Q34922985-207F82F7-3AB9-41C2-9E3C-5915140F8366 Q34979163-B6C9FBB1-D93E-49A8-826D-5AEA007EB945 Q35197271-6B2877A5-64E3-4F7C-A3D4-D622A51C7370 Q35567215-701BCE25-F4A6-4641-B77A-557A795684A4 Q35822619-14D1520E-BD67-4FF0-B419-ECBA70AC2F3B Q36175327-ECC9A560-9C31-4ACF-A6BB-59CDC97BDD41 Q36365764-7FB8E6F0-ED68-4A9F-9F72-2E912FC52E2C Q36387228-17C557A7-B299-4365-A1B0-75191D539671 Q36505647-4D9BE186-580F-4B85-AC1C-2FBAB3EA976C Q36601983-08E5972B-B07D-4DD0-B86E-FF532ACC19CC Q36655192-BA9C271C-4E45-43A5-B80C-0DFCDAF2F2F9 Q36709101-1582E519-4193-456C-937C-F917E21C65F7 Q36875347-6F752995-2132-456E-8BD8-3C1B8A4B9F37 Q36969787-99CC9EB5-E9D0-465C-9DCB-925F29842F08 Q37188867-1ADDBC1F-1154-413C-8BA9-3D9B7858C744 Q37254475-60F99C27-6C70-4871-B77C-24BEA631073E Q37415420-CDDF3A7B-CC54-4B14-B488-CE21697C2112 Q37538618-15D0D1C4-6522-4E3F-A7C0-9BC69EB46675 Q37692595-00895A41-B976-434F-BF07-F5B6C4D29BEB Q37698620-25A402FB-13F2-4376-AABA-3163EF6A3286 Q37704651-0D1D3040-505B-4F09-BDAF-5D787D7989CB Q38152999-9BD3168B-ED8B-43FE-8D09-A06D04A51590 Q38170326-4CBBD0D9-4B4B-45B9-B192-687D3BE04790 Q38211726-3764539E-EE54-4D40-806E-55070F3C3310 Q38217388-CAB95958-B83F-477B-8A70-320DD4DCB6D0 Q38263295-9884D1C5-A63E-475E-A822-5EBD55F13B48 Q38787356-CF4F3FD5-5E7B-4355-9A58-BCA299A83859 Q38912920-92889899-AAFC-47C1-9933-E35FD0893E3B

P2860

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

http://www.wikidata.org/entity/Q33625213

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.

@ast

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.

@en

type

label

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.

@ast

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.

@en

prefLabel

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.

@ast

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.

@en

P1433

Q33625213-E5CBB676-34D7-4146-84F9-0B475D751736

P1476

Q33625213-ACF8D4F0-F074-41B6-8712-205AFFA320B9

P2093

Q33625213-47480A0D-C46A-492E-A44F-7FCA5F0353FD

Q33625213-74C983EF-53B3-45A2-8C82-CD4BF592DA81

Q33625213-AB5A7E89-42F3-4CA2-95CB-BB30CB2DE210

Q33625213-D4DB2FBC-B026-4503-8A42-E0879675870F

Q33625213-E3D86E67-A646-44C9-8907-730BB62F85BF

Q33625213-EF4CB734-96F8-4983-9B4D-E0E8D9AAFD19

Q33625213-FF99BBE2-0197-4D97-970D-5518E74DEA2C

P2860

Q33625213-07D320E6-785D-4F55-9B58-6BE14CE0496C

Q33625213-27670958-FBA7-45A9-8DDF-8944717D8402

Q33625213-297FE863-3B7B-4E73-9C85-84583B4DE2F3

Q33625213-2BC75D67-DC26-4D22-A082-B5D9B1856DA1

Q33625213-2E94C1AF-4099-4D5C-A212-5F1A9938DE61

Q33625213-2F86D5C1-8B85-478B-AAAE-B077346E235B

Q33625213-3E6EF0A7-7E35-42CF-ADF1-86F6B34A3779

Q33625213-47327303-3908-4BDE-831D-AF92030EAAED

Q33625213-49E601F7-121E-4F89-9152-B5512C22D1BD

Q33625213-4FE25BED-82AA-4C01-BFF6-F5673479B1AC

P304

Q33625213-604D6F2A-AEB5-4631-A368-23908E554CD8

P31

Q33625213-E3641362-61A2-44D3-BDC9-174B02599A7B

P356

Q33625213-A22700B1-8E20-4DBD-A0A2-12696D56758A

P407

Q33625213-1B40A653-6D60-4998-8158-E2339A20DC7B

P433

Q33625213-7AEE572E-83B3-4943-88AA-18BDCA739856

P478

Q33625213-A322A46F-9E08-4D6C-895C-FC0004D7F3C2

P50

Q33625213-74083CBB-965C-45D6-B2A2-A0EDEEA10CCB

Q33625213-788A4304-428F-40EE-8977-F44F7A8515C4

Q33625213-B689C63E-2E5D-4C8B-A722-1D000EC11995

P577

Q33625213-A1A64F3F-B7DD-424D-ACB6-9B50746216FB

P698

Q33625213-0EFA4BC3-937A-4D44-BB63-FBD8E57B57FE

P921

Q33625213-A6E2AC1B-7D10-44C3-8080-CB036166FD79

P932

Q33625213-562BB47C-7BC7-4012-A75B-A6613956E020

P356

QAD.0B013E328357F5AD

P1433

P1476

Long-acting nanoformulated ant ...... HIV-1-infected humanized mice

@en

P2093

Howard E Gendelman

http://www.w3.org/2001/XMLSchema#string

Joellyn McMillan

http://www.w3.org/2001/XMLSchema#string

Prasanta K Dash

http://www.w3.org/2001/XMLSchema#string

Rodney L Mosley

http://www.w3.org/2001/XMLSchema#string

Santhi Gorantla

http://www.w3.org/2001/XMLSchema#string

Shantanu Balkundi

http://www.w3.org/2001/XMLSchema#string

Yazen Alnouti

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals

Progress in antiretroviral drug delivery using nanotechnology

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.

Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

Opportunistic bacterial infections in breeding colonies of the NSG mouse strain.

The critical need for alternative antiretroviral formulations, and obstacles to their development.

P304

2135-2144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E328357F5AD

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Larisa Poluektova

Harris A Gelbard

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22824628

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4024396

http://www.w3.org/2001/XMLSchema#string